TY - CHAP M1 - Book, Section TI - Scleroderma (Systemic Sclerosis) A1 - Mandal, Jennifer A1 - Boin, Francesco A2 - Stone, John H. Y1 - 2021 N1 - T2 - Current Diagnosis & Treatment: Rheumatology, 4e AB - Scleroderma (systemic sclerosis) is a systemic autoimmune disease characterized by varying degrees of skin fibrosis, vascular damage, and a wide array of internal organ dysfunction.Most manifestations of scleroderma fall into two main categories: fibrotic disease (such as skin tightening and interstitial lung disease [ILD]) and vascular disease (such as Raynaud phenomenon [RP] and pulmonary arterial hypertension [PAH]).In limited cutaneous scleroderma, skin involvement remains confined to the distal extremities (fingers, toes) and face. In contrast, in the diffuse form of scleroderma, skin tightening extends proximal to the elbows and knees as well as the trunk. Both limited and diffuse scleroderma can have significant internal organ involvement.RP and antinuclear antibodies (ANA) positivity are each present in more than 95% of scleroderma patients. When either of these features is missing, an alternative diagnosis should be strongly considered.Some patients with scleroderma develop clinical features overlapping with other rheumatic disorders such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory myopathy, and Sjögren syndrome.It is helpful to take an organized organ-by-organ approach to assess an individual patient’s specific manifestations, disease activity, extent of damage, and treatment options.There is no “universal” pharmacologic intervention for scleroderma that treats the disease as a whole. Combination therapy is most effective to address the heterogeneous nature of this disease manifestation. SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/04/16 UR - accessmedicine.mhmedical.com/content.aspx?aid=1180196883 ER -